Fumigillol compounds and methods of making and using same

Patent metadata

Field	Value
Publication number	US-10220015-B2
Application number	US-201815869368-A
Country	US
Kind code	B2
Filing date	Jan 12, 2018
Priority date	May 9, 2012
Publication date	Mar 5, 2019
Grant date	Mar 5, 2019

Abstract

The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.

First claim

We claim:

1. A method of treating and/or controlling obesity in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of:

and pharmaceutically salts or stereoisomers thereof, and a pharmaceutical carrier.

2. A method of inducing weight loss in a patient in need thereof, comprising administering to said patient an effective amount of the composition of claim 1 .

3. The method of claim 1 , wherein the patient is a human.

4. The method of claim 1 , wherein the patient has a body mass index greater than or equal to about 25 kg/m 2 before the administration.

5. The method of claim 1 , wherein the compound is administered orally, intravenously, or subcutaneously.

6. The method of claim 1 , wherein the compound is administered orally.

Assignees

• Zafgen Inc

Inventors

• Zahler Robert
• Vath James E

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• C07D303/31 Primary

  in which the oxirane rings are condensed with a carbocyclic ring system having three or more relevant rings · CPC title

• A61K31/336 Primary

  having three-membered rings, e.g. oxirane, fumagillin · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title